Table 1 Mice analyzed for the impact of oncRAS on ERMS precursor lesions.

Treatment	Number of animals	Median overall survival (range)	Healthy // early death	Mice with ERMS (palpable and non-palpable)	Mice with palpable ERMS	Mice with ≥ 2 ERMS (palpable and non-palpable)	Median latency time of palpable ERMS	Further findings (number of animals)
Ptch^+/−HRas^fl/+Myf5^CreER/wt
Control	30	200 days (65–211)	18 // 12	17 (57 %)	14 (47 %)	6 (20 %)	97 days	Cysts/Cavernous angioma(4), Medullo-blastoma(3), Papilloma (1)
Tamoxifen	29	200 days (78–204)	19 // 9	22 (76 %)	19 (66 %)	6 (21 %)	85 days	Cysts/Cavernous angioma(4), Medullo-blastoma(1), Papilloma (1)
Ptch^+/−KRas^fl/+Myf5^CreER/wt
Control	21	200 days (83–209)	14 // 7	9 (43 %)	8 (38 %)	4 (19 %)	103 days	Cysts/Cavernous angioma (2), Medullo-blastoma (3)
Tamoxifen	24	122 days (69–204)	6 // 18	20 (83 %)	17 (58 %)	12 (50 %)	85 days	Cysts/Cavernous angioma (4), Medullo-blastoma (0)
Ptch^+/−NRas^fl/+Myf5^CreER/wt
Control	26	200 days (131–212)	20 // 6	16 (62 %)	14 (54 %)	10 (38 %)	70 days	Cysts/Cavernous angioma (4), Medullo-blastoma (2)
Tamoxifen	26	200 days (76–206)	21 // 5	19 (73 %)	17 (65 %)	8 (31 %)	94 days	Cysts/Cavernous angioma (6), Medullo-blastoma (1)
Ptch^+/−
Control	24	200 days (60–208)	20 // 4	12 (50 %)	12 50 %)	3 (13 %)	80 days	Cysts/Cavernous angioma (5), Medullo-blastoma (0)
Tamoxifen	26	200 days (90–209)	19 // 7	12 (46 %)	12 (46 %)	4 (15 %)	105 days	Cysts/Cavernous angioma (4), Medullo-blastoma (2)

The ERMS-like tumors develop mostly at the extremities. They may also develop in muscles of the belly and the back. Intraperitoneal localized tumors were discovered by manual palpation or upon autopsy, as were very small tumors. There were no significant differences in tumor locations between the genotypes. Medulloblastomas harm the animals. These mice were immediately sacrificed and checked for non-palpable ERMS. The coloring of the table is very confusing.

Search